a type of advanced stage lung cancer (called small cell lung cancer) that has spread or grown and you have tried at least two different types of chemotherapy, including one that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
For Patients With Metastatic Melanoma (3 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO is approved for both BRAF+ and BRAF- patients. OPDIVO was approved for BRAF+ metastatic melanoma patients based on the amount of time patients lived without their tumors worsening. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). OPDIVO in combination with YERVOY was approved based on the amount of time patients lived without their tumors worsening. There is ongoing eva luation of clinical benefit of OPDIVO in combination with YERVOY for this use.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
To Help Prevent a Skin Cancer Called Melanoma From Coming Back After It and the Affected Lymph Nodes Have Been Removed by Surgery (4 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
For Adults With Kidney Cancer (Renal Cell Carcinoma) That Has Spread (5 of 12)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat kidney cancer (renal cell carcinoma) in certain people when their cancer has spread.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
For Previously Treated Patients With Advanced Renal Cell Carcinoma (6 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
For Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) That Has Returned or Spread After Previous Treatment (7 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.
For People With Liver Cancer (Hepatocellular Carcinoma) That Have Received Treatment With Nexavar® (sorafenib) (8 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with liver cancer (hepatocellular carcinoma) after you have received treatment with Nexavar® (sorafenib). OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing eva luation of clinical benefit of OPDIVO for this use.
For Previously Treated Patients With Advanced Bladder Cancer (Urothelial Carcinoma) (9 of 12)
OPDIVO® (nivolumab) is a prescription medicine used to treat people with bladder cancer (urothelial carcinoma) that has spread or grow |
